Two large firms -- Roche and GlaxoSmithKline -- have started evaluating every new drug candidate for its potential to be abused by athletes and have promised to share information about these medicines with WADA, The New York Times reported.
Several other smaller drug makers have provided WADA with information about specific drugs.
Until recently, drug makers paid little attention to how their products could be abused by athletes, according to David Howman, director general of WADA. Previously, drug companies "felt that any publicity in relation to anti-doping control would be negative," he told The Times. "But what they discovered is the opposite happened."
Copyright © 2012 HealthDay. All rights reserved.